RxDoctor Payments Data

Trudy Lovejoy

Family · Clemson, SCNPI 1255589313

Payments from drug & device makers

$8,948in general payments, 2019–2025

Across 494 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$672
  • Acadia Pharmaceuticals Inc$642
  • Teva Pharmaceuticals USA, Inc.$519
  • Pfizer$486
  • Lundbeck LLC$417
  • plus $5K from 45 others

What the payments were for

  • Consulting fees$1502%
  • Food & beverage$8,78698%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,948 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$37,900
Medicare patients
304
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate30$374,987
Kesimpta PenOfatumumab22$245,460
UbrelvyUbrogepant112$182,791
Nurtec OdtRimegepant Sulfate81$125,667
Dimethyl Fumarate28$103,080
QuliptaAtogepant73$93,458
Aimovig AutoinjectorErenumab-Aooe104$89,809
CopaxoneGlatiramer Acetate14$82,539
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$54,212
KeppraLevetiracetam12$51,738
FycompaPerampanel37$43,868
Emgality PenGalcanezumab-Gnlm35$29,669
Topiramate ErTopiramate19$27,931
Keppra XrLevetiracetam17$26,182
VimpatLacosamide11$20,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$301$374,98730 claims
AbbVieUbrelvy, Qulipta$1,659$276,248185 claims
PfizerNurtec Odt, Lyrica$486$138,160106 claims
Teva Pharmaceuticals USA, Inc.Copaxone$519$82,53914 claims
UCB, Inc.Vimpat, Briviact, Neupro$143$49,75936 claims
Eisai Inc.Fycompa$253$43,86837 claims
Neurocrine Biosciences, Inc.Ongentys$337$7,21211 claims
Upsher-smith Laboratories LLCTopiramate$18$3,255159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →